新型ESAT6-CFP10皮肤试验诊断结核感染的敏感性与特异性及安全性:中国两项随机、自身对照、平行组2b期试验
该研究在中国成人中开展两项随机平行组临床试验,共纳入777名健康参与者和96名结核患者,评估ESAT6-CFP10(EC)皮肤试验诊断结核感染的准确性及安全性。结果显示,1.0 μg/0.1 mL剂量EC皮肤试验的曲线下面积为0.95,与T-SPOT.TB相比敏感性和特异性相似,且不受卡介苗接种影响,未观察到相关严重不良事件。
要点
- EC皮肤试验(1.0 μg/0.1 mL)诊断结核感染的AUC为0.95。
- EC皮肤试验敏感性和特异性与T-SPOT.TB相似。
- EC皮肤试验诊断准确性不受卡介苗接种影响,安全性良好。
核心结论
- EC皮肤试验在1.0 μg/0.1 mL剂量下具有高敏感性和特异性,与T-SPOT.TB相当,且不受卡介苗接种影响。
研究设计与样本
- 两项随机、自身对照、平行组2b期临床试验,纳入777名健康参与者和96名结核患者,分别接受1.0 μg/0.1 mL或0.5 μg/0.1 mL EC皮肤试验。
主要发现
- 与T-SPOT.TB相比,EC皮肤试验敏感性为87.5(95%CI 77.8-97.2) vs 86.5(95%CI 79.5-93.4),特异性为98.9(95%CI 96.0-99.9) vs 96.1(95%CI 93.5-97.8)。
- 在卡介苗接种参与者中,EC皮肤试验与T-SPOT.TB一致性高达96.3(95%CI 92.0-100.0)。
- 未观察到与EC皮肤试验相关的严重不良事件。
临床怎么用
- EC皮肤试验可作为结核感染诊断的辅助工具,尤其适用于卡介苗接种人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnostics to identify tuberculosis infection are limited. We aimed to assess the diagnostic accuracy and safety of ESAT6-CFP10 (EC) skin test for tuberculosis infection in Chinese adults. METHODS: We conducted 2 randomized, parallel-group clinical trials in healthy participants and tuberculosis patients. All participants were tested with the T-SPOT.TB test, then received an EC skin test and tuberculin skin test (TST). The diameter of skin indurations and/or redness at injection sites were measured at different time periods. A bacillus Calmette Guerin (BCG) model was established to assess the diagnosis of tuberculosis infection using an EC skin test. RESULTS: In total, 777 healthy participants and 96 tuberculosis patients were allocated to receive EC skin test at 1.0 μg/0.1 mL or 0.5 μg/0.1 mL. The area under the curve was 0.95 (95% confidence interval [CI], .91-.97) for the EC skin test at 1.0 μg/0.1 mL at 24-72 hours. Compared with the T-SPOT.TB test, the EC skin test demonstrated similar sensitivity (87.5, 95% CI, 77.8-97.2 vs 86.5, 95% CI, 79.5-93.4) and specificity (98.9, 95% CI, 96.0-99.9 vs 96.1, 95% CI, 93.5-97.8). Among BCG vaccinated participants, the EC skin test had high consistency with the T-SPOT.TB test (96.3, 95% CI, 92.0-100.0). No serious adverse events related to the EC skin test were observed. CONCLUSIONS: The EC skin test demonstrated both high specificity and sensitivity at a dose of 1.0 μg/0.1 mL, comparable to the T-SPOT.TB test. The diagnostic accuracy of the EC skin test was not impacted by BCG vaccination. CLINICAL TRIALS REGISTRATION: NCT02389322 and NCT02336542.
引用
- Xu M, Lu W, Li T, et al. Sensitivity, Specificity, and Safety of a Novel ESAT6-CFP10 Skin Test for Tuberculosis Infection in China: 2 Randomized, Self-Controlled, Parallel-Group Phase 2b Trials. Clin Infect Dis. 2022. PMID: 34021314. doi:10.1093/cid/ciab472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。